XML 63 R23.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment and Geographic Data | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Segment and Geographic Data | SEGMENT AND GEOGRAPHIC DATA On January 1, 2024 we adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which expands disclosure requirements to require entities to disclose significant segment expenses that are regularly provided to or easily computed from information regularly provided to the chief operating decision maker. We have updated our disclosures to include our significant segment expenses that are regularly provided to our chief operating decision maker (CODM). We segregate our operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics which aligns to our internal reporting structure and how our CODM assesses the performance of and allocates resources. The CODM is the Chief Executive Officer. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using segment operating income. Our reportable segments and related disclosures reflect certain reclassifications of prior year amounts from our Orthopaedics segment to our MedSurg and Neurotechnology segment due to changes in our internal reporting structure. The Corporate and Other category shown in the table below includes corporate and administration, corporate initiatives and share-based compensation, which includes compensation related to employee stock options, restricted stock units and performance stock unit grants and director stock options and restricted stock unit grants.
Segment Results | 2024 |  | 2023 |  | 2022
MedSurg and Neurotechnology | $ | 13,518 |  |  | $ | 12,163 |  |  | $ | 10,893 |
Orthopaedics | $ | 9,077 |  |  | 8,335 |  |  | 7,556 |
Net sales | $ | 22,595 |  |  | $ | 20,498 |  |  | $ | 18,449 |
MedSurg and Neurotechnology | $ | 5,320 |  |  | $ | 4,876 |  |  | $ | 4,637 |
Orthopaedics | $ | 2,400 |  |  | 2,254 |  |  | 1,920 |
Cost of sales | $ | 7,720 |  |  | $ | 7,130 |  |  | $ | 6,557 |
MedSurg and Neurotechnology | $ | 784 |  |  | $ | 702 |  |  | $ | 682 |
Orthopaedics | $ | 540 |  |  | 508 |  |  | 477 |
Segment research, development and engineering expenses | $ | 1,324 |  |  | $ | 1,210 |  |  | $ | 1,159 |
MedSurg and Neurotechnology | $ | 3,203 |  |  | $ | 2,934 |  |  | $ | 2,564 |
Orthopaedics | $ | 3,111 |  |  | 2,922 |  |  | 2,608 |
Segment selling, general and administrative expenses | $ | 6,314 |  |  | $ | 5,856 |  |  | $ | 5,172 |
MedSurg and Neurotechnology | $ | 208 |  |  | $ | 181 |  |  | $ | 178 |
Orthopaedics | 433 |  |  | 386 |  |  | 350 |
Segment depreciation and amortization | $ | 641 |  |  | $ | 567 |  |  | $ | 528 |
Corporate and Other | 162 |  |  | 139 |  |  | 123 |
Amortization of intangible assets | 623 |  |  | 635 |  |  | 627 |
Total depreciation and amortization | $ | 1,426 |  |  | $ | 1,341 |  |  | $ | 1,278 |
MedSurg and Neurotechnology | $ | 4,004 |  |  | $ | 3,470 |  |  | $ | 2,831 |
Orthopaedics | 2,591 |  |  | 2,265 |  |  | 2,202 |
Segment operating income | $ | 6,595 |  |  | $ | 5,735 |  |  | $ | 5,033 |
Items not allocated to segments: |  |  |  |  |
Corporate and Other | $ | (880) |  |  | $ | (780) |  |  | $ | (649) |
Inventory stepped up to fair value | (46) |  |  | — |  |  | — |
Acquisition and integration-related charges | (108) |  |  | (20) |  |  | (138) |
Amortization of intangible assets | (623) |  |  | (635) |  |  | (627) |
Structural optimization and other special charges | (138) |  |  | (170) |  |  | (295) |
Goodwill and other impairments | (977) |  |  | (36) |  |  | (270) |
Medical device regulation | (58) |  |  | (96) |  |  | (140) |
Recall-related matters | (40) |  |  | (18) |  |  | 15 |
Regulatory and legal matters | (36) |  |  | (92) |  |  | (76) |
Consolidated operating income | $ | 3,689 |  |  | $ | 3,888 |  |  | $ | 2,841 |
Segment Assets and Capital Spending
Assets: | 2024 |  | 2023 |  |
MedSurg and Neurotechnology | $ | 23,115 |  |  | $ | 20,804 |  |  |
Orthopaedics | 18,507 |  |  | 18,023 |  |  |
Total segment assets | $ | 41,622 |  |  | $ | 38,827 |  |  |
Corporate and Other | 1,349 |  |  | 1,085 |  |  |
Total assets | $ | 42,971 |  |  | $ | 39,912 |  |  |
Purchases of property, plant and equipment: | 2024 |  | 2023 |  | 2022
Orthopaedics | $ | 230 |  |  | $ | 179 |  |  | $ | 173 |
MedSurg and Neurotechnology | 276 |  |  | 183 |  |  | 175 |
Total segment purchases of property, plant and equipment | $ | 506 |  |  | $ | 362 |  |  | $ | 348 |
Corporate and Other | 249 |  |  | 213 |  |  | 240 |
Total purchases of property, plant and equipment | $ | 755 |  |  | $ | 575 |  |  | $ | 588 |
We measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges, structural optimization and other special charges, goodwill and other impairments, reserves for certain product recall matters and reserves for certain legal and regulatory matters. Identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. Corporate assets are principally property, plant and equipment and noncurrent assets. The countries in which we have local revenue generating operations have been combined into the following geographic areas: the United States; Europe, Middle East, Africa; Asia Pacific; and other foreign countries, which include Canada and countries in the Latin American region. Net sales are reported based on the geographic area of the Stryker location where the sales to the customer originated.
Geographic Information
| Net Sales |  | Net Property, Plant and Equipment
| 2024 |  | 2023 |  | 2022 |  | 2024 |  | 2023
United States | $ | 16,943 |  |  | $ | 15,257 |  |  | $ | 13,638 |  |  | $ | 1,997 |  |  | $ | 1,874 |
Europe, Middle East, Africa | 2,897 |  |  | 2,618 |  |  | 2,348 |  |  | 1,260 |  |  | 1,151 |
Asia Pacific | 2,020 |  |  | 1,946 |  |  | 1,885 |  |  | 75 |  |  | 77 |
Other countries | 735 |  |  | 677 |  |  | 578 |  |  | 116 |  |  | 113 |
Total | $ | 22,595 |  |  | $ | 20,498 |  |  | $ | 18,449 |  |  | $ | 3,448 |  |  | $ | 3,215 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration